Mesoblast offers an extraordinary gap between current price and analyst consensus — over 116% potential upside at roughly 34-to-1 reward versus geometric downside — but the stock is in a falling-knife formation, burns cash at over 100% of revenues, operates with zero reported margins, and quality scores well below minimum thresholds; the asymmetric geometry is notable but the entry setup is not confirmed.
Thesis pillars
- Cash Burn Zero Margin Profile→Stable
- Extreme Asymmetric Upside Geometry→Stable
- Falling Knife Technical Profile→Stable
- +1 more pillar — see the Why tab for full reasoning
Mesoblast Limited (MESO) Stock Analysis
Recovery setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $14.31: Quality below floor (2.3 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.2/10 and A.R:R 11.8:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Rich valuation; Below long-term trend.
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company's proprietary regenerative medicine technology platform is based on specialized cells known as... Read more
Sell if holding. Engine safety override at $14.31: Quality below floor (2.3 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.2/10 and A.R:R 11.8:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Rich valuation; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 53. Score 4.2/10, moderate confidence.
Passes 7/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity 53d clear, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
Recent developments
updated 2026-07-07Recent Developments — Mesoblast Limited
Latest news
- NEWS 8 Health Care Stocks With Whale Alerts In Today’s Session — benzinga Jul 6, 2026 neutral
- NEWS Reported Earlier, Mesoblast Secures BLA Filing Number For Rexlemestrocel-L, Backed By Orphan Drug And RMAT Designations — benzinga Jul 1, 2026 positive
- NEWS 10 Health Care Stocks With Whale Alerts In Today’s Session — benzinga Jun 29, 2026 neutral
- NEWS ON Semiconductor, SanDisk And Other Big Stocks Moving Lower In Friday’s Pre-Market Session — benzinga Jun 26, 2026 neutral
- NEWS Reported Earlier, Mesoblast Strengthens Balance Sheet With $50M Drawdown From Five-Year Non-Dilutive Facility, Retiring — benzinga Jun 25, 2026 positive
Generated 2026-07-07T11:31:44Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Clinical-stage biotech: losses expected pre-commercialisation. Quality floor doesn't distinguish R&D investment from operational decay — components above tell the real story.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $14.31: Quality below floor (2.3 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.2/10 and A.R:R 11.8:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Rich valuation; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 53. Prior stop was $13.33. Score 4.2/10, moderate confidence.
Take-profit target: $29.75 (+107.6% upside). Prior stop was $13.33. Stop-loss: $13.33.
Quality below floor (2.3 < 4.0); Value-trap signals (3/5): Revenue declining (-84.8% YoY), Margin compression (op margin -13930.7%), Material insider selling (3 sells, 0.11% of cap).
Mesoblast Limited trades at a P/E of N/A (forward -205.4). TrendMatrix value score: 0.0/10. Verdict: Sell.
10 analysts cover MESO with a consensus score of 4.1/5. Average price target: $35.
What does Mesoblast Limited do?Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in...
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. The company is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for the treatment or prevention of chronic heart failure; MPC-25-IC for the treatment or prevention of acute myocardial infarction; and Ryoncil for the treatment of pediatric SR-aGVHD; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.